Economy / FinanceQ, [DS] & Corruption

COVID-19 Breakingviews | AstraZeneca’s messaging warrants a review, too


AstraZeneca’s vaccine home run is in danger of turning into a curveball. The $134 billion drug giant is planning to review its Covid-19 vaccine candidate to clarify how effective it is. While it’s doing so, the UK group should probably do a separate review of how it communicates. Chief Executive Pascal Soriot said on Monday that AstraZeneca’s Covid-19 vaccine could be 90% effective. That was the first data point in a statement released by the company, but referred to a result from a small part of the study accidentally obtained by using the wrong dosage. Meanwhile the University of Oxford,…

This content is for Q17 Membership, Classified Membership, and LifeTime Patriot Membership members only.
Login Join Now
QNavy is a pool a 3 former Navy Officers, U.S. Navy & French Navy, who served proudly their countries, specialized in conflict analysis as per their respective skills & experience on Special Ops. #NavyVetUnited

COVID-19 | SARS-CoV-2: lab-origin hypothesis gains traction

Previous article

The Hunters Become The Hunted, Tide Is Turning, Final Stage – Ep. 2339

Next article

You may also like


Comments are closed.